Efficacy and safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML subpopulation from phase 2 and ascertain phase 3 studies

Phase 1 study evaluating Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients

Randomized phase 2 study to assess safety and efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients: interim safety analysis

Phase 2 study of Oral Decitabine and Cedazuridine in combination with Magrolimab for previously untreated subjects with intermediate to very high-risk Myelodysplastic Syndromes (MDS)

Patients’ perspectives on Oral Decitabine and Cedazuridine for the treatment of Myelodysplastic Syndromes

Demographic and clinical characteristics among patients with Myelodysplastic Syndromes receiving oral Decitabine and Cedazuridine or intravenous/subcutaneous hypomethylating agents in a real-world setting